Illumina 'Wasting Court Time' With Deal Overtures, FTC Says
By Bryan Koenig ( July 21, 2021, 8:59 PM EDT) -- Federal Trade Commission staffers contesting biotech giant Illumina's planned $8 billion purchase of cancer detection company Grail assailed the companies Tuesday for seeking a settlement conference in the in-agency challenge process, arguing the firms aren't sincere and are really just trying to get an advanced peak at FTC tactics....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.